Contrast agent manufacturer Guerbet posted revenue increases for the third-quarter and nine-month periods of its fiscal 2017.
For the quarter (end-September 30), the company posted revenue of 194.3 million euros ($227 million), up 4.2% after currency adjustments, compared with the same period in 2016. For the first nine months of 2017, Guerbet posted revenue of 601.4 million euros ($703 million), up 5.8% after currency adjustments.
In its MRI segment, Guerbet's revenue increased by 14.4% to 207.5 million euros ($243 million), which it attributed to the sales performance of its Dotarem macrocyclic MRI contrast agent. Sales in the company's x-ray segment rose 1.5% to 277.4 million euros ($324 million), driven by Optiray sales, while its Imaging Solutions and Services segment increased by 4.8% to reach 59.3 million euros ($69 million).
However, on the interventional radiology and theranostic side, sales fell by 4.7% to 38.4 million euros ($45 million) due to supply difficulties, Guerbet said.
